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Background: Tungiasis (sand flea disease) is caused by the penetration of female sand fleas (Tunga penetrans,
Siphonaptera) into the skin. It belongs to the neglected tropical diseases and is prevalent in South America, the
Caribbean and sub-Saharan Africa. Tungiasis predominantly affects marginalized populations and resource-poor
communities in both urban and rural areas. In the endemic areas, patients do not have access to an effective
and safe treatment. A proof-of-principle study in rural Kenya has shown that the application of a two-component
dimeticone (NYDA®) which is a mixture of two low viscosity silicone oils caused almost 80% of the embedded sand
fleas to lose their viability within 7 days.
Methods: In this study we compared the efficacy of two distinct modes of application of NYDA®; one targeted
application to the area where the parasite protrudes through the skin and one comprehensive application to the
whole foot.
Results: Independent of the two modes of application, the dimeticone caused more than 95% of embedded sand
fleas to lose all signs of viability within 7 days. The targeted application killed embedded sand fleas more rapidly
compared to when the whole foot was covered. The proportion of viable lesions at day two were 7.0 versus 23.4%
(p < 0.01) and at day five 3.9 versus 12.5% (p < 0.02).
Conclusions: Our findings suggest that the dimeticone could provide a safe and effective treatment for tungiasis in
areas with difficult access to health care.
Trial registration: ISRCTN ISRCTN74306878
Keywords: Tungiasis, Treatment, Dimeticone, Public healthBackground
Tungiasis (sand flea disease) belongs to the family of
neglected tropical diseases and is prevalent in South
America, the Caribbean and sub-Saharan Africa [1]. It is
caused by penetration of female sand fleas (Tunga pene-
trans) into the skin and the ensuing inflammatory response* Correspondence: per.nordin@skaraborg-institute.se
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(http://creativecommons.org/publicdomain/ze[2]. The inflammation is intensified by an almost unavoid-
able bacterial super-infection [3]. Just about all of the le-
sions are found in the feet [4, 5]. The consequences of sand
flea disease are debilitating, eventually leading to chronic
morbidity with impaired mobility and quality of life [6, 7].
The prevalence of tungiasis varies between settings;
prevalences up to 60% have been reported in various
populations with up to 80% in children [8–11]. Children
and the elderly are more likely to develop severe disease
[4, 11, 12]. Tungiasis predominantly affects marginalized
populations and people living in resource-poor commu-
nities in both urban and rural areas [8, 10, 13–15].le is distributed under the terms of the Creative Commons Attribution 4.0
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against embedded sand fleas in humans. Randomized
controlled trials using topical or oral administration of
antihelminthic drugs such as metrifonate, thiabendazole
or ivermectin showed little or no efficacy at all [16–19].
The only treatment option patients in the endemic areas
have is to try to kill embedded sand fleas chemically or
mechanically. People often apply toxic substances such as
kerosene, used engine oil or household insecticides.
Alternatively, the lesions are manipulated with sharp
instruments such as needles, safety pins, razor blades or
thorns, a health risk by itself. Such practices can also cause
additional bacterial super-infections or transmit viral
pathogens such as HBV, HCV and HIV [7].
The last three abdominal segments of an embedded sand
flea form a miniature cone through which the parasite re-
mains in contact with the environment through an opening in
the skin of about 250 μm. Through this opening, the female
sand flea takes up oxygen, expels eggs, defecates and gets
fertilized. The abdominal cone protrudes through the skin
and has been identified as a target for drug treatment [20, 21].
As the skin around the abdominal cone is painful, patients
usually know exactly how to localize an embedded sand flea.
A proof-of-principle study in rural Kenya has shown that
the application of a two-component dimeticone (NYDA®)
to the skin of the feet, repeated two times within 5 min, kills
almost 80% of the embedded fleas within 7 days [21]. Fur-
thermore, assessments of lesion morphology indicate that
normal development was interrupted in those parasites not
killed: the female fleas became unable to produce and/or
expel eggs. Lesion-associated inflammation significantly
decreased within 7 days after application of dimeticone [21].
NYDA® contains two dimeticones or silicone oils with
different viscosities and a high creeping property. It is
commercialized as a medical device for the treatment
of head lice infestation in many European countries
[22, 23]. Its mode of action is purely physical [24].
In this study, we compared the efficacy of two distinct
modes of application of NYDA®: one targeted application
to the area where the abdominal cone of the parasite
protrudes through the skin and one general application to
the whole foot.
The rationale for the targeted application was twofold: first,
to minimize the volume of the dimeticone and, second, to
direct the dimeticone to where it should act, namely the vital
organs of the parasite located inside the abdominal cone. By
consequence, a targeted application of the dimeticone should
lead to a more rapid death of an embedded sand flea.Fig. 1 Sampling of the patients, allocation of feet to treatment arms
and number of lesions includedMethods
The study took place from the end of February till the
end of March 2014, i.e. during the end of the dry season,
when transmission of tungiasis peaks.Study area
The study was conducted in eight primary schools in Bugiri
district, Bulidha sub-county, eastern Uganda. The schools
were located in the following villages: Makoma, Isaka
Bisolo, Kibuye, Businda, Busakira, Nakawa and Wakawaka.
Study population
Sixty children aged 5 to 12 years selected from eight
primary schools were included in the study. The number
of children sampled from each school was based on the
school and class size as well as on the organizational
convenience. The number of children enrolled per
school varied from 3 to 21.
Children from classes one to six present at the day of
the investigation were eligible for the study provided
they had at least three viable sand flea lesions on each
foot (stage 2 and/or 3 according to the Fortaleza
classification [25]) as evaluated by a rapid assessment
method [26].
They should furthermore not show clinical symptoms
requiring immediate medical attention such as abscesses,
ulcers or intense pain. When multiple embedded sand
fleas of stage 2 or 3 were present, only lesions which
could be clearly distinguished from one another were
included in the study.
Lesions were chosen so that their location made it
possible to use the handheld digital microscope, such as
at the toe, the sole or the rim of the foot. Each lesion
was photographed, and its location and stage was noted
in the patient’s record. The number of lesions included
in the study was limited to three per foot and were
followed up at regular intervals for 7 days (Fig. 1).
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Two topical regimens of the two-component dimeticone
(NYDA®) (Pohl-Boskamp GmbH & Co. KG, Hohenlockstedt,
Germany) were randomly allocated to either the left
or the right foot of the patient. Before the application
of dimeticone, both feet were washed with water and
soap and dried with a clean towel.
The regimens were labeled ‘whole foot treatment’ and
‘targeted treatment’. Whole foot treatment meant that
dimeticone was applied to the skin of the foot up to the
ankle, as previously described [21]. The application was
stopped when the skin became shiny, indicating that it
was wetted with the dimeticone. This procedure was
repeated three times within 10 min and required 2 to
5 ml depending on the size of the foot.
Targeted treatment meant that dimeticone was aspired
into a 5-ml syringe to which a flexible tube was mounted.
Three drops were applied to the area where the parasite’s
abdominal cone protruded through the skin. One drop
corresponds to approximately 50 μl of dimeticone. This
procedure was repeated three times within 10 min to en-
sure that a maximum amount of dimeticone entered into
the abdominal cone of the parasite within a short period
of time. This required approximately 450 μl per embedded
sand flea. In both groups, the dimeticone was only applied
at baseline.
For each patient, demographic data as well as baseline
parasitological measurements were conducted as previ-
ously described [21, 25, 27]. Staging was performed ac-
cording to the Fortaleza Classification.
 Stage I: penetrating sand flea
 Stage II: brownish-black dot with a diameter of
1-2 mm
 Stage III: circular yellow-white watch glass-like
patch with a diameter of 3–10 mm and with a
central black dot
 Stage IV: brownish-black crust with or without
surrounding necrosis
Stage I to III are viable sand fleas; in stage IV, the
parasite is dying or already dead [25].
Using a digital handheld microscope (dnt DigiMicro
Mobile 5-megapixel-handheld-microscope, ITEZ, Hong
Kong, China) viability signs (expulsion of eggs, excre-
tion of faeces threads, excretion of liquid, pulsations/
contractions) were recorded as present or not.
Outcome measures
All data were collected by the same investigator at
baseline and during a 7-day follow-up: day two, day five
and day seven.
Two major outcome measures were defined: the viabil-
ity of the embedded sand flea and the intensity of thelocal inflammation. The primary outcome measure was
the viability of the embedded sand flea according to the
Fortaleza Classification [25]. An embedded sand flea was
considered to be dead, if none of the four viability signs
was detected during 15 min of observation by the digital
handheld microscope on two consecutive follow-up
examinations [20]. A secondary outcome measure was
the intensity of the local inflammation, as assessed semi-
quantitatively by an inflammation score [21]. Lesions
manipulated by the patient or the caregiver were also
documented.
Another set of outcome measures were based on vis-
ual scales depicting how the impact of tungiasis was
perceived by the patient. The scales consist of a series
of simple pictures illustrating itching, pain, itching-
related sleep disturbance, pain-related sleep disturbance
and mobility impairment as perceived by the patient.
The patient was asked to classify the degree of each com-
plaint by pointing to the corresponding picture. Zero
meant no complaint at all, 1 = little complaint, 2 = moder-
ate complaint, 3 = severe complaint and 4 = very severe
complaint. These outcome measures encompass both feet,
since it was considered impossible for the participants to
discern the impact of embedded sand fleas separately for
each foot.
Statistical methods
The sample size of circa 140 lesions per treatment
group is based on a 15% difference in treatment effect,
a power of 90% and a significance level of 5%. The as-
sumption was based on our previous findings [21].
Fisher’s exact test was used to compare proportions,
and the Kruskal-Wallis test was used to analyze the
inflammation score and self-reported tungiasis-related
characteristics. A relationship was considered statisti-
cally significant when a p value was less than 5%. All
presented confidence interval (CI) have a confidence
level set at 95%.
Results
Baseline
At baseline, the two treatment groups displayed similar
characteristics concerning the distribution of lesion types
(Table 1).
The difference between the number of lesions found
on the two feet for the same individual were never larger
than 12 in all cases except one. In this particular case,
the foot intended for whole foot treatment had 75
lesions and the foot intended for targeted treatment only
nine lesions. The distribution of differences in number
of lesions between the paired feet, i.e. feet on the same
individual are considered a pair, showed a mean of 0.1
together with a standard deviation of 9.7, and the related
median had a value of 0. The average numbers of viable
Table 1 Types of lesions at baseline in the two treatment
groups
Whole foot treatment Targeted treatment
Lesion typea Median (Min–max) Median (Min–max)
Viable lesion 4 (1–75) 5 (1–50)
Non-viable lesion 4 (0–30) 4 (0–30)
Manipulated lesion 1 (0–12) 1 (0–15)
All lesions 9 (1–94) 10 (2–70)
aAccording to definition in subjects and methods
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variation in both treatment groups. The two groups also
displayed a similar distribution of frequencies across the
range of the parasites’ developmental stages (Table 2).During and after treatment
The outcome measured as the loss of viability of embed-
ded sand fleas after the application of the dimeticone is
shown in Fig. 2.
At the first follow-up, 2 days after treatment, the
number of viable parasites decreased significantly in
both groups (whole foot treatment p < 0.001; targeted
treatment p < 0.001). The loss of viability was higher in
the targeted treatment group (p < 0.001). At the second
follow-up, after 5 days, the loss of viability was still
higher in the targeted treatment group compared to the
whole foot treatment group (p < 0.02). After 7 days, the
reduction of the number of viable sand fleas was similar
in both groups: 95% (CI 92; 99) of the parasites in the
whole foot treatment group had lost all signs of viability
and 97% (CI 94; 99) in the targeted treatment group
(Table 3). Furthermore, in both groups, sand fleas which
remained viable did not expel eggs during the 7 days.
Whether lesions were in stage 2 or 3 at baseline had no
impact on the efficacy of either treatment (Table 3).
The inflammation scores and the visual scale measure-
ments showed significant reductions between baseline
and day seven (Table 4).
After completion of the study (day 7), the medians of
all visual scales had decreased to 0.Table 2 Number of viable lesions per developmental stage of
lesions in the two treatment groups at baseline





Total number 139 146
aAccording to the Fortaleza classification [25]Discussion
Tungiasis is endemic in resource-poor populations in
many countries of sub-Saharan Africa (8, 10, 13, 14, 15).
It is associated with important morbidity, and children
and the elderly carry the highest disease burden (4, 11,
12). Nonetheless, hitherto there is no approved treat-
ment. In Kenya, the Ministry of Health recommends
bathing the feet for 10 min in KMnO4, an approach with
a rather low efficacy [21]. Besides, KMnO4 stains the
skin in deep purple. This makes the treatment visible for
everyone and the patient vulnerable to ridiculosity [21].
Hence, there is an urgent need for a safe and effective
treatment of tungiasis.
The study showed that with the targeted application
of the dimeticone, parasites were killed more rapidly
and that 2 days after the topical application, only 7%
of the parasites remained viable (Table 3). After
7 days, though, in both treatment groups, >95% of
the embedded sand fleas had lost all viability signs. A
more rapid death of the parasites is an advantage,
because inflammation resolves as soon as an embed-
ded sand flea has died (Thielecke M, unpublished
observation 2014, [28]).
It is likely that by a repeated targeted application,
more dimeticone crept into the abdominal cone per
unit of time compared to when the skin of the whole
foot is wetted and that this resulted in a rapid death.
Actually, when looking at the abdominal cone with the
digital microscope, one could see how the dimeticone
creeps into the opening in the skin and then disappears,
as it spreads to the microscopic surfaces located within
the abdominal cone. A similar observation has been
made when dimeticone is applied to free running insects
such as head lice and crickets [23].
Seven days after the application of the dimeticone,
98% of the parasites had lost all their viability signs in
the targeted treatment group and 95.5% in the whole
foot treatment group. Only a few sand fleas withstand
the treatment, but these were not observed to expel eggs
during the remainder of the study, indicating that the
dimeticone had abrogated the normal development of
the female sand flea as observed previously [21]. The
implication of this finding is that a scaled-up treatment
program could have an effect on the transmission.
Tungiasis-related symptoms decreased rapidly, when
the sand fleas lost their viability by the dimeticone. This
was visible both as indicated by the inflammation score
assessed by the investigator, as well as by the visual
scales as expressed by the patients themselves (Table 4).
Notably, the median became 0 7 days after treatment in
all visual scales. One week after treatment, healing was
evident as seen by the decrease in the inflammation
score as well as the visual scales confirming a previous
finding [21].
Fig. 2 Decline of parasite viability from baseline with treatment for each group through the three follow-up examinations at day 2, day 5 and day 7
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inflammation around the embedded sand fleas increase
when they continue to grow and intensify their meta-
bolic activity in stages 2 and 3 [27]. The inflammation
recedes, however, when the parasites develop from stage
3 to 4 [25]. In these stages, the signs of viability slowly
disappear and eventually the parasites die.
The efficacy of the whole foot treatment here was
higher compared to the proof-of-principle study in
Kenya where dimeticone applied to the feet up to ankles
killed 78% of the embedded sand fleas within 7 days
[21]. Apart from the difficulty of achieving a standard-
ized application procedure giving a precise dosage for
each foot, there are also biological explanations for thisTable 3 Viability of embedded sand fleas in the treatment groups a
Whole foot treatment
Lesion stageb No. viable No. non-viable
Baseline (day 0) All lesions 139 0
stage 2 126 0
stage 3 13 0
First follow-up (day 2) All lesions 32 105
stage 2 31 92
stage 3 1 13
Second follow-up (day 5) All lesions 15 105
stage 2 14 95
stage 3 1 10
Third follow-up (day 7) All lesions 6 128
stage 2 5 115
stage 3 1 13
n.a. not applicable
aNot all participants and all lesions could be examined at every occasion, which exp
bAccording to the Fortaleza classification [25]difference. Rapid penetration of the dimeticone into
the last abdominal segments of the embedded sand
flea may depend on how deep a parasite is located in
the skin. The thicker the corneal layer of the skin,
the longer the dimeticone will need to reach the
stratum of the epidermis in which the parasites are
located. In addition, only a part of the dimeticone will
be absorbed by a rough and thickened epidermis. The
children in Kenya did not use shoes at all, whereas
the children in Uganda, at least partially, had sandals
or flip-flops. Thus, the higher efficacy of the dimeti-
cone in this study might reflect a thinner and
smoother corneal layer of the feet of the Ugandan
participants.t baseline and the subsequent follow-upsa
Targeted Treatment
Viable (%) No. viable No. non-viable Viable (%) p value
100 146 0 100 n.a.
100 132 0 100 n.a.
100 14 0 100 n.a.
23.4 10 132 7.0 <0.001
25.2 8 116 6.5 <0.001
7.1 2 16 11.1 0.600
12.5 5 122 3.9 0.018
12.8 5 109 4.4 0.030
9.1 0 13 0 0.458
4.5 3 137 2.1 0.326
4.2 3 120 2.4 0.496
7.1 0 17 0.0 0.452
lains differences in the numbers of examined lesions during follow-ups
Table 4 Secondary outcome measures at baseline and at day seven for both feet combined
Baseline Day 7
Outcome N Median IQRa Min Max N Median IQRa Min Max p valueb
Inflammation score 56 4.3 3.4 1 22 57 0.5 1.5 0 12 <0.001
Visual scales
Intensity of spontaneous pain 60 3 1 1 4 60 0 1 0 4 <0.001
Intensity of itching 60 3 1 1 4 60 0 1 0 3 <0.001
Itch-related sleep disturbance 60 2 1 1 4 60 0 1 0 4 <0.001
Pain-related sleep disturbance 60 2 1 1 4 60 0 0 0 3 <0.001
Degree of mobility impairment 52 2 1 1 4 59 0 1 0 4 <0.001
aInterquartile range
bKruskall-Wallis test
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the rim of the foot were deliberately chosen so that the
handheld digital microscope easily could be applied in
order to assess viability signs with a higher degree of
precision. At those selected sites, it can be suspected
that the dimeticone might be targeted more precisely
and/or penetrate the parasite more rapidly. No such
selections were made in the Kenyan study. There, the
included lesions were also located under the nail, under
thick crusts of the corneal layer or in necrotic tissue
areas into which the dimeticone cannot penetrate easily.
A difference in penetration efficiency could thus possibly
also explain the differing results.
The number of lesions varied considerably within the
group of included children (Table 2). When the number
of lesions are more than three, they often occur in
clusters [29] making it difficult to distinguish the charac-
teristics of an individual lesion, which also impairs
assessments of morphological changes and the lesion-
associated inflammation [21]. We, therefore, deliberately
limited the number of included lesions to three per foot.
The results of this study are based on highly controlled
and monitored procedures. This means one ought to be
cautious when considering the true effectiveness of
treatment of tungiasis with dimeticone under field
conditions. Based on the average required volume of
dimeticone for treatment of the whole foot and what is
used in the targeted treatment, we find that the targeted
application is more parsimonious as long as the number
of viable embedded sand fleas does not exceed seven
lesions per foot. Hence, in severe cases where individuals
suffer from dozens of embedded viable sand fleas, the
whole foot treatment should be more cost-effective and
also more practicable.
Conclusions
The application of a mixture of a two-component dimeti-
cone (NYDA®) caused more than 95% of embedded sand
fleas to lose all defined signs of viability within 7 days. The
targeted topical application worked faster compared towhen the whole foot was covered. Our findings suggest
that the dimeticone could provide a safe and effective
treatment for tungiasis in areas with difficult access to
health care.
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